New data on APIVaults release functionality Roskilde October 21. 2021 The encapsulation retains the payload until a well-defined percentage of the BC membrane has been digested by the cellulase. When this digestion threshold has been reached there is a sudden change in permeability and the payload is fully released over a short span of time. […]
New data on APIVaults release functionality Read More »
Apillet to participate in BIOTECHGATE DIGITAL PARTNERING Roskilde April 15. 2021 Apillet will attend the international partnering-event BIOTECHGATE DIGITAL PARTNERING May 3 – 7, 2021 that gathers decision-makers from the industry. We are looking for an investor / financing, for clients and partners and for R&D collaborations and partnerships. Please get in touch if you
Apillet to participate in BIOTECHGATE DIGITAL PARTNERING Read More »
Apillet enters into collaboration with BCTechnology Roskilde April 1. 2021 Apillet announces the start of a new collaboration with BCTechnology, Braga Portugal on the the development of a protoptype and an industrial master formula for APIVAULT, Apillets novel gastro-resistant enteric encapsulation technology. We are very happy to have signed a contract with BCTechnology on the
Apillet enters into collaboration with BCTechnology Read More »
Apillet receives angel investment Roskilde March 20. 2021 Apillet ApS has secured the financing of the prototype and industrial master formula development of APIVAULT, Apillets novel gastro-resistant enteric encapsulation technology. The project paves the way to preclinical testing of the APIVAULT technology. The financing is in the form of an angel investment. Apillet is actively looking for additional investments or
Apillet receives angel investment Read More »
Apillet receives investment from Innovation Fund Denmark Roskilde, Denmark, December 21 2020 Apillet has secured soft funding through an Innobooster investment from Innovation Fund Denmark. This enables initiation of key activities with international partners, including development of a prototype of and an industrial master formula for APIVAULT, Apillets novel gastro resistent enteric encapsulation Technology. The
Apillet receives investment from Innovation Fund Denmark Read More »
Partnering conference 3 7 – 10 December, 2020 Apillet was represented by CEO Anders Christensen and strategic advisor Michael Plougmann at the BioFit virtual partnering conference . Apillet was invited to participate in a business pitch session. The pitch was given on the 7th of December the first day of the conference. The pitch presented
Partnering conference 3 Read More »
Partnering conference 2 23 – 26 November, 2020 CEO Anders Christensen and strategic advisor Michael Plougmann represented Apillet in the Biotechgate Digital Partnering virtual business development event. More than 10 selected partnering meetings were conducted. Thank you for all the valuable discussions and opportunities that emerged from this event.
Partnering conference 2 Read More »
Partnering conference 1 5th November, 2020 Apillet participated in the Developments and Innovations in the Drug Delivery Market meeting. Thank you so much for the conversations that resulted from this event.
Partnering conference Read More »
Apillet to participate in The Future of Swedish & Danish Life Science 2020 September 29, 2020 Apillet will attend this international partnering-event that gathers decision-makers from the industry. Please get in touch if you would like to schedule a meeting with Apillet
Apillet to participate in The Future of Swedish & Danish Life Science 2020 Read More »
Scientific advisory board announcement 2 Roskilde, Denmark, July 22 2020 Apillet Announces Dr. Fernando Dourado will Join the Scientific Advisory Board to Aid Apillet’s Efforts on the Development of AP-002 – A gastro-resistant enteric coating for oral formulations of sensitive pharmaceuticals based on bacterial cellulose and cellulases.
Scientific advisory board announcement 2 Read More »